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Background  The NUBPL gene was first reported as a cause of mitochondrial complex 
I deficiency (MIM 613621, 618242) in 2010. To date, only eight patients have been 
reported with this mitochondrial disorder. Five other patients were recently reported to 
have NUBPL disease but their clinical picture was different from the first eight patients. 
Here we report clinical and genetic findings in five additional patients (four families). 
Methods  Whole exome sequencing was used to identify patients with compound 
heterozygous NUBPL variants. Functional studies included RNA-Seq transcript 
analyses, missense variant biochemical analyses in a yeast model (Yarrowia lipolytica), 
and mitochondrial respiration experiments on patient fibroblasts. 
Results The previously reported c.815-27T>C branch-site mutation was found in all four 
families. In prior patients, c.166G>A [p.G56R] was always found in cis with c.815-
27T>C, but only two of four families had both variants. The second variant found in 
trans with c.815-27T>C in each family was: c.311T>C [p.L104P] in three patients, 
c.693+1G>A in one patient, and c.545T>C [p.V182A] in one patient. Complex I function 
in the yeast model was impacted by p.L104P but not p.V182A. Clinical features include 
onset of neurological symptoms at 3-18 months, global developmental delay, cerebellar 
dysfunction (including ataxia, dysarthria, nystagmus, and tremor), and spasticity. Brain 
magnetic resonance imaging showed cerebellar atrophy. Mitochondrial function studies 
on patient fibroblasts showed significantly reduced spare respiratory capacity.  
Conclusion  We report on five new patients with NUBPL disease, adding to the number 
and phenotypic variability of patients diagnosed worldwide, and review prior reported 











Complex I deficiency is the third most common mitochondrial disorder and is highly 
heterogeneous, clinically and genetically. Human complex I has 44 different subunits 
that are encoded by nuclear and mitochondrial genes[1]. To date, pathogenic variants 
have been identified in 34 genes[2] and a molecular diagnosis is commonly achieved in 
~50% of affected individuals[3]. Additionally, there are at least 16 genes that play a role 
in the assembly of complex I, of which 12 have been identified to cause autosomal 
recessive disease[4, 5]. One such assembly factor is nucleotide binding protein like 
(NUBPL), which was first  identified as Ind1 in the yeast Yarrowia lipolytica[6]. Depletion 
of human or yeast NUBPL protein leads to decreased complex I activity[6, 7]. 
Variants in the NUBPL gene (MIM 613621) were first associated with 
complex I deficiency (MIM 618242) in 2010 in a whole exome sequencing (WES) 
study of over 100 patients with clinical and biochemical evidence of complex I 
deficiency[3]. One patient was identified initially with a point mutation in the paternal 
copy of NUBPL (c.166G>A [p.G56R]), while the maternal copy had a large 
chromosomal rearrangement that disrupts NUBPL. However, a protein variant 
carrying only the p.G56R substitution was able to rescue complex I activity in 
patient fibroblasts, suggesting it was not pathogenic[8]. Further sequence analysis 
revealed an intronic variant, c.815‐27T>C on the paternal copy, which affects a 
splicing branch site[3, 8]. A subset of the c.815‐27T>C transcripts lack exon 10, 
leading to a frameshift and truncated protein product. Interestingly, the c.815‐27T>C 
variant is found in ~1% of European ancestry subjects (Finnish plus non-Finnish) in 
the Genome Aggregation Database (gnomAD)[9].  
Subsequently, six additional patients were identified from a magnetic resonance 
imaging (MRI) database of more than 3,000 subjects with unclassified 
leukoencephalopathy. These cases were recognized by specific MRI features including 
diffuse leukodystrophy involving the cerebellar cortex, periventricular deep and 
subcortical white matter and corpus callosum with some cystic changes[10]. All patients 
from this study had c.815-27T>C in cis with c.166G>A plus a second deleterious 
NUBPL variant in trans, with the exception of one patient that is presumed to be 
homozygous for c.815-27T>C and c.166G>A. With recent reports on three more 
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families, there are now 14 patients (in 11 families) reported to have NUBPL disease[3, 
10-15]. Here, we now report clinical features of five additional patients in four families, 
plus functional and biochemical experiments as supporting evidence for complex I 
deficiency in these patients. We also review the spectrum of genotypes and phenotypes 
found in all known cases of NUBPL disease.  
 
MATERIALS AND METHODS 
 
Patients 
Institutional Review Board (IRB) approval was obtained from the University of California, 
Irvine for this study. Informed consents were obtained from the parents of the children 
who participated in this study, in addition to consent from one patient over the age of 18 
years. 
WES was used for identification of the NUBPL variants at Baylor Genetics 
(Houston, TX), at GeneDx (Gaithersburg, MD), or as described previously[12, 16, 17], 
with the exception of Patient 1B (Sanger sequencing). Thoughout the manuscript, all 
NUBPL variants are described based on NM_025152.3. Brain MRIs for all patients and 
a cerebellar brain biopsy for Patient 1A were provided by the referring physicians. 
 
RNA splicing analysis 
Splicing analysis of NUBPL variant c.815-27T>C was performed using CloneSeq, an 
RNA sequencing (RNA-Seq) assay based on cloning of RT-PCR products followed by 
massively parallel sequencing of the cloned transcripts[18]. Briefly, total RNA was 
isolated from whole blood from the proband, both parents, an affected sibling, and an 
unaffected sibling of Family 1. RT-PCR was perfomed on cDNA derived from mRNA 
only using the following primers: 5’-ATGGTATTGCTTGTATGTCTATGG-3’, and 5’-
GTTCCATCACCACATTGCTG-3’. Transcript levels (Sashimi plots) and the percentage 
of aberrantly spliced transcripts was determined as described previously[18]. 
 
Mitochondrial respiration assays 
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The Seahorse assay system (Agilent, Santa Clara, CA), which directly measures the 
oxygen consumption rate (OCR), was used for mitochondrial respiration studies[19]. 
Human fibroblasts from three NUBPL patient cell lines (patients 1A, 1B, and 2) and one 
control line were cultured in DMEM supplemented with 10% fetal bovine serum, 5 mM 
Glucose, 1 mM pyruvate, and 1X non-essential amino acids, penicillin, streptomycin, 
and amphotericin B (Gibco). The day prior to the assay, patient and control fibroblasts 
were seeded onto 24-well Seahorse XF24 Cell Culture Microplates at a density of 
30,000 cells/well (~1x105 cells/cm2) and incubated overnight in a humidified 5% CO2 
37°C incubator. 
 After 18 hours incubation, cells were assayed using a Seahorse XF Cell Mito 
Stress Test Kit and XFe24 analyzer according to the manufacturer's protocol[19]. 
Cellular bioenergetic profiles were measured by three serial injections of four reagents 
at 1 µM final concentration each: oligomycin, which inhibits ATP synthase (complex V); 
carbonyl cyanide-4 (trifluoromethoxy) phenylhydrazone (FCCP), a proton ionophore that 
induces uncoupling of ATP synthesis from electron transfer and is thus a measure of 
maximal respiration; and a mixture of rotenone plus antimycin A, which completely 
inhibits electron transport to enable measurement of non-mitochondrial respiration. Data 
were normalized to total protein per well using the Bio-Rad DC protein assay. The XF 
Mito Stress Test report generator was used to calculate basal respiration, ATP turnover 
rate, proton leak, and maximal and spare respiratory capacity for each cell line (patient’s 
fibroblasts were assayed in triplicate). 
 
Yeast model functional studies 
The functional effect of the NUBPL variants was tested in Yarrowia lipolytica as 




We report on genetic and clinical findings in four families, three of which contain 
individuals with mitochondrial dysfunction symptoms consistent with complex I 
deficiency due to autosomal recessive NUBPL mutations. Pedigree charts for the 
7 
 
families are shown in Figure 1A (Family 1 has two patients) and brain MRIs for the 
patients are shown in Figure 1B. Cerebellar brain biopsy results are shown in Figure 1C 
for Patient 1A. Detailed clinical descriptions for each patient are reported in the 
Supplementary Data file. Below, molecular, clinical, and functional findings are reported 
for the five new patients plus genotype-phenotype comparisons to all previously 
reported NUBPL patients. 
 
Molecular diagnosis of new patients 
 
Genetic analysis using WES revealed compound heterozygous variants in the NUBPL 
gene (Tables 1 and 2). All patients were heterozygous for the common c.815-27 T>C 
variant (present in ~1% of European ancestry subjects) found in the first reported 
case[3]. The missense variant c.166G>A [p.G56R], present in cis with c.815-27T>C in 
all previously reported cases, was found in Families 2 and 3 (Figure1A, Table 1). 
However, we report, for the first time, patients without c.166G>A, see Families 1 and 4 
(Figure 1A, Table 1). 
 Missense variant c.311T>C [p.L104P] was found in trans with c.815-27T>C in 
Families 1 and 3. It is predicted to be damaging/deleterious (Table 2) and was shown to 
be pathogenic in a yeast model[12]. It was first reported in a 2014 WES study[16] to 
cause complex I deficiency in Patient 1A; however, no clinical details were provided. 
Subsequently, it was reported for two conditions[11, 13] with overlapping phenotypes 
(see below) wherein patients are compound heterozygotes with missense variants 
p.D96V or p.F242L (Tables 1, 2) instead of c.815-27T>C. 
 In Family 2, the patient was found to be compound heterozygous for previously 
reported variants[10], c.815-27T>C and c.166G>A in cis plus the splice donor mutation 
c.693+1G>A in trans (Figure 1A, Table 1). In Family 4, the patient was found to be 
compound heterozygous for c.815-27T>C and newly reported variant c.545T>C 
[p.V182A], which is predicted to be damaging/deleterious (Table 2) but our yeast model 



























New patients – compound heterozygotes with c.815-27T>C 
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+ A, D, N, T +, + na, – na, na  16, Newh 
 1B 6 3 F   + A, D, N, T +, + na, na na, na  New 
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+ A, D, N, S + na, – na, + Leigh-like 17, Newh 
Suspected patient – compound heterozygote with c.815-27T>C 
4i 
USA 






+ N – na, na –, na 16p12.1 
deletion 
New 










+ A, D, N, S – +, + +, +  3, 8 
6k 
France 
6 23 toddler M c.815-27T>C 





+ A, D, N + na, + na, na  14 
7l 
Argentina 




+ A, N, S + na, na –, na  10 
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(hemi. or hom. suspected) 
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+ A, D, N, S –, + +, na +, +  10 
9 
Canada 






+ A, D, N + +, – –, na  10 
 9B 7 13 F   + A, D, N –, + +, + +, +   
10 
USA 






+ A, D, N, S – na, na +, na  10 
11 
Netherlands 






+ A, D, S – +, + +, +  10 
12 
Germany 
12 na na na c.815-27T>C 





na na na na, na na, na  12 
Previously reported patients – compound heterozygotes without c.815-27T>C 
13 
UK 




+ D, H + na, na na, na dystonia, 
BSN 
11 


















+ H, N, S +, + +, na +, na thalamic 
involvement 
15 




a Age at last clinical assessment (rounded to whole year) 
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b Inheritance (Inh.) indicated as paternal (pat), maternal (mat), unknown (unk); not applicable (na) listed for patients that did not have the c.166G>A [p.G56R] variant 
c Common clinical features: A = ataxia, D = dysarthria, H = hypotonia, N = nystagmus, S = spasticity, T = tremor (intention) 
d Cerebellar atrophy determined from early and/or late MRI (a single entry indicates only one MRI was available/done): + = present, – = absent, na = MRI not available or not 
done 
e Complex I (CI) deficiency (def.) defect reported for fibroblast (first entry) or muscle (second entry): + = present, – = absent, na = test data not available or not done 
f High lactate reported for plasma (first entry) or CSF (second entry): + = present, – = absent, na = test data not available or not done 
g Other clinical details: Family 2 patient, infantile neuroaxonal dystrophy 1 (INAD) considered but genetic testing was negative; Family 13 patients have dystonia and bilateral 
striatal necrosis (BSN); Family 14 patient is reported to have multi-systemic involvement, including renal tubular acidosis, osteoporosis, hepatomegaly, growth hormone 
deficiency (short stature present), and interstitial lung disease 
h Patient mutations previously reported but without clinical information: Patient 1A, Farwell et al. 2015 Supplemental data16; Patient 3, Posey et al. 2016 Supplemental data17 
i Patient 4 was suspected to have NUBPL disease, but his brain MRI and p.V182A functional experiments (yeast model) are not supportive of complex I deficiency (see text) 
j Family 5 was reported to be from Australia by Kevelam et al. 201310, but is actually from New Zealand (NZ) per personal communication from D. Thorburn 
k Family 6 patient’s c.815-27T>C variant was reported as c.815-217T>C (likely a typographical error for c.815-27T>C) and p.D273Qfs*32 (likely p.D273Qfs*31), see Tenisch et 
al. 201214 
l Family 7 patient is thought to be hemizygous or homozygous for c.166G>A [p.G56R] and c.815-27T>C [p.D273Qfs*31], see Discussion 
m Full variant name is c.667_668insCCTTGTGCTG 





Table 2. Variants reported in autosomal recessive NUBPL diseasea: functional impact and population frequency. 
  Functional impact  Family number (Table 1) gnomAD EUR subjectsh 






5 7d 6e 13 14 1 3 9 15 4f 11 8 2 10 12g Hom/Het/Total Allele 
frequency 
Del/Dup Disrupted LOF na ©               Novel 0 
c.166G>A p.G56R +, + na © © ?    © ©   © © © © ? 1/37/64,144 0.0003040 
c.205_206delGT p.V69Yfs*80 LOF na   ©             0/0/56,617 0 
c.287A>T p.D96V +, – na    ©            Novel 0 
c.311T>C p.L104P +, + +, +    © © © ©         0/30/64,317 0.0002332 
c.313G>T p.D105Y +, + +, +        ©        0/5/64,314 0.0000389 
c.351G>A p.M117I +, + na         ©       Novel 0 
c.545T>C p.V182A +, + –, –          ©      1/541/64,243 0.0042260 
c.579A>C p.L193F +, + +, +           ©     Novel 0 
c.667_668insi p.E223Afs*4 LOF na            ©    Novel 0 
c.693+1G>A Splicing 
defectj 
LOF na         ©    © ©  0/3/56,513 0.0000265 
c.726C>G p.F242L +, + na     ©           0/3/56,090 0.0000267 
c.815-27T>C Splicing 
defectj 
LOF +, + © © ©   © © ©  © © © © © © 3/568/64,114 0.0044760 
c.859G>T p.G287C +, + –, +               © Novel 0 
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a See Table 1 Reference column (Ref) for patient case report citations. 
b In silico prediction (LOF or Polyphen2, SIFT): loss-of-function (LOF); Polyphen2, + = possibly or probably damaging, – = benign; SIFT, + = deleterious, – = 
tolerated 
c Yeast model (Yarrowia lipolytica) study, see Maclean et al. 201812 and Figure 4: first entry, + = severely or slightly decreased complex I level, – = normal 
complex I level; second entry, + = impaired growth in cold, – = normal growth in cold; na = not applicable or not done 
d Family 7 patient is thought to be hemizygous or homozygous for c.166G>A [p.G56R] and c.815-27T>C [p.D273Qfs*31], see Discussion 
e Family 6 patient’s c.166G>A [p.G56R] genotype is unknown (?); his c.815-27T>C variant was reported as c.815-217T>C (likely a typographical error for c.815-
27T>C) and p.D273Qfs*32 (likely p.D273Qfs*31), see Tenisch et al. 201214 
f Patient 4 was suspected to have NUBPL disease, but his brain MRI and p.V182A functional experiments (yeast model) are not supportive of complex I 
deficiency (see text) 
g Family 12 patient’s c.166G>A [p.G56R] genotype is unknown (?) 
h gnomAD is the Genome Aggregation Database, see Karczewski et al. 20199: EUR subjects correspond to Non-Finnish European (NFE) ancestry; population 
information reports the number of homozygous (Hom), heterozygous (Het), and total (Total) subjects with the variant and the corresponding allele frequency 
i Full variant name is c.667_668insCCTTGTGCTG 




Clinical findings of new patients 
 
Primary clinical features of Patients 1-5 (3 females and 2 males) are summarized in 
Table 1; detailed clinical descriptions for each patient are provided in the 
Supplementary Data file. All patients are of European ancestry (USA-based) and at last 
evaluation are aged 3-19 years. Onset of neurological symptoms ranged from birth to 
18 months and included global developmental delay, cerebellar dysfunction (ataxia, 
dysarthria, dysmetria, nystagmus, and intentional tremor), hyperreflexia with clonus, 
and, in Patient 3, a Leigh-like phenotype. Patient 2 was initially thought to have infantile 
neuroaxonal dystrophy 1 (INAD, MIM 256600) and Patient 4 also has a 16p12.1 
deletion[21], which may be contributing to his symptoms. 
 All five patients had delays in their gross motor skills and are able to walk with 
assistance. Gaits of Patients 1A and 2 were described as  wide-based and ataxic, while 
Patient 3 walked with a narrow/scissoring (diplegic) gait. All patients have difficulties 
with their fine motor skills (especially with tremor) except Patient 2, whose tremor has 
improved with the help of occupational therapy and, potentially (parental report, see 
Supplementary data), from treatment with EPI-743. Patients 1A and 4 have language 
delay while the others have slurred speech. Patient 3 has right sensorineural hearing 
loss. Cognition level varies, but is impaired for all except for Patient 2 who has a normal 
IQ. Brain MRIs for all five patients are shown in Figure 1B. Cerebellar atrophy was 
noted in all patients except for Patient 4. Cerebellar biopsy results for Patient 1A are 
shown in Figure 1C. 
 
Functional studies of new patients 
 
Aberrant splicing is observed for NUBPL c.815-27T>C carriers 
 
Transcript variants in Family 1 carriers  and non-carriers of NUBPL c.815-27T>C were 
assessed by CloneSeq analysis[18]. The two most abundant abnormal transcripts were 
r.815-72_815-1ins72 (partial intron 9 inclusion) and r.815_897del83 (exon 10 skipping), 
as shown in the Sashimi plots (Figure 2A). Transcript variant r.815-72_815-1ins72 was 
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essentially not observed in non-carriers of c.815-27T>C, but was found in the carriers 
(observed reads were 239 for Sister+, 198 for Proband+, and 129 for Father+). 
Whereas transcript variant  r.815_897del83 was observed in all members of Family 1, 
but higher levels were found in carriers of c.815-27T>C (observed reads were 629 for 
Sister+, 410 for Proband+, and 801 for Father+) compared to non-carriers (observed 
reads were 245 for Mother- and 59 for Sister-). Relative levels of the two transcript 
variants, r.815-72_815-1ins72 and r.815_897del83, are reported as PSI (Figure 2B), a 
measure of how efficiently sequences of interest are spliced into transcripts. This 
analysis shows that 5-20% of transcripts expressed by c.815-27T>C carriers contain 
partial intron 9 inclusion (r.815-72_815-1ins72) but it is not observed in non-carriers. 
Skipping of exon 10 (r.815_897del83) was observed in ∼25% of transcripts expressed 
by the carriers, but only ~5% of non-carriers. These results are consistent with aberrant 
splicing data previously reported for a complex I deficiency patient with the c.815-27T>C 
variant[8]. 
 
Mitochondrial function is impaired in patient fibroblasts 
 
Fibroblasts from three NUBPL patient cell lines (Patients 1A, 1B, and 2) and one control 
cell line were used to perform in vitro mitochondrial respiration studies (Figure 3). Basal 
respiration was not significantly different in the NUBPL patient fibroblast cells compared 
to control cells, nor was ATP production (post-oligomycin injection) or non-mitochondrial 
respiration (post-rotenone + antimycin A injection). However, spare respiratory capacity, 
which is the difference between maximal respiration (post-FCCP injection) and basal 
respiration, was significantly reduced in all three NUBPL patient fibroblast cells as 
compared to the control cells (Figure 3B). This is in contrast to the negative results 
found by the clinical electron transport chain analyses of Patient 1A’s muscle or Patient 
2’s fibroblasts (see Table 1). 
 




The c.815-27T>C variant, found in all four families, was previously shown to result in 
synthesis of a truncated protein, p.D273QfsX31, in addition to reduced amounts of 
normal NUBPL protein[8]. The equivalent truncated protein product in Yarrowia, 
p.N271QfsX31, is less stable and severely affected the assembly of complex I[20]. 
The p.L104P substitution, present in Families 1 and 3, changes a highly 
conserved amino acid in a protein motif involved in ATP hydrolysis. The equivalent 
substitution caused instability of the Yarrowia Ind1 protein and decreased complex I 
levels to ~30% of the control line[12]. 
 The p.V182A substitution is only found in Family 4. In the Yarrowia Ind1 protein, 
valine is semi-conserved and aligns with a methionine (Figure 4A). Therefore, to match 
the human sequence, first methionine was substituted by valine (p.M180V), both of 
which have large non-polar side chains. Next, methionine was changed to alanine 
(p.M180A), which has a much shorter side chain. These changes were neutral with 
respect to complex I levels (Figure 4B). 
 When the Yarrowia IND1 gene is deleted (ind1Δ), a 160-kDa assembly 
intermediate containing the NUCM subunit (NDUFS2 in human) accumulates[12]. This 
intermediate has been observed in all Ind1 protein variants tested so far, including the 
p.G136D variant (p.G138D in human), which has otherwise no discernable phenotypes. 
In contrast, the assembly intermediate was not observed in p.M180V or p.M180A 
(Figure 4C). Another feature of ind1 mutants is a striking growth defect at low 
temperature[12]. When the p.M180V and p.M180A variants were grown at 10 C, 
colonies grew to the same size as in the control strain, whereas the ind1Δ mutant did 
not grow at all (Figure 4D). Taken together, the biochemical and phenotypic tests in 
Yarrowia yeast show that substitution of M180 with valine or alanine in Ind1 does not 
have an effect on complex I, but they do not rule out a potential effect of the valine to 
alanine substitution on the function of human NUBPL. We note that the V182A variant is 
predicted to be possibly damaging/deleterious (Table 2). 
 




Table 1 summarizes the main clinical features in our five new patients reported here, 
plus twelve previously reported patients (19 patients total in 15 families). Patients are 
sub-grouped based on whether they have the c.815-27T>C branch-site mutation, which 
is found in 14 of 19 patients. Phenotypes for this subset of patients have greater overlap 
than with patients without the c.815-27T>C variant (Families 13-15). We note that 
clinical information was not available for German Patient 12 and USA Patient 4 is listed 
separately as NUBPL disease is suspected but not supported by his brain MRI (Figure 
1B) or functional experiments on the p.V182A variant (Figure 4).  
 Notably, all patients had developmental delay with onset as infants or toddlers. 
Cerebellar dysfunction symptoms (ataxia, dysarthria, nystagmus, and tremor) were 
prevalent in patients with the c.815-27T>C branch-site mutation, but absent (Patient 14) 
or minimal (Patients 13A,13B, 15A, and 15B) in patients without this mutation. Spasticity 
was reported in 6 of 14 patients with c.815-27T>C and 3 of 5 patients without this 
mutation. Brain MRIs revealed cerebellar atrophy in 13 of 18 patients who underwent at 
least one assessment but this symptom may not be present at an early age (e.g., 
Patients 8 and 9B were only positive in a later MRI and Patients 5, 10 and 11 were 
negative in an early MRI but no late MRI results were available). 
  Biochemical assays for complex I defects (electron transfer) and lactate levels 
(plasma and/or CSF) can be inconclusive. For example, results were reported for 12 of 
19 patients but only 9 of 12 patients tested positive for a complex I defect and/or a high 
lactate level. 
 Patient 2 is the first unrelated case of NUBPL disease that has identical 
mutations to those reported in a previous case (Patient 10, Table 1)[10]. Ataxia is the 
main overlapping cerebellar symptom for these two patients and both were noted to 
have normal intelligence. Cerebellar atrophy was noted in Patient 2’s MRI obtained at 
age 3 years (Figure 1B), but not in Patient 10’s MRI obtained at age 1.5 years old (no 
late MRI was available). Previously reported Patients 15A and 15B[15] also have 
c.693+1G>A (but lack c.815-27T>C) and have thalamic involvement in addition to 
cerebellar atrophy. 
 Patients 1A, 1B, and 3 share nearly identical variants (patients 1A and 1B do not 
have c.166G>A [p.G56R]) and their overlapping cerebellar symptoms include ataxia, 
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dysarthria, and nystagmus, while spasticity was only reported in Patient 3. All three 
patients showed cerebellar atrophy in their MRIs (Figure 1B) and electron transport 
chain assays for Patients 1A and 3 were both negative for a complex I defect (Table 1). 
Interestingly, while previously reported Patients 13A, 13B, and 14[11, 13] share the 
c.311T>C [p.L104P] mutation (but lack c.815-27T>C) with Patients 1A, 1B, and 3, their 
main clinical features are distinct (Table 1). Patients 13A and 13B have dystonia and 
bilateral striatal necrosis (BSN) and Patient 14 lacks cerebellar symptoms but has renal 
tubular acidosis, osteoporosis, hepatomegaly, and growth hormone deficiency.  
 
Genetic comparison of all NUBPL patients 
 
Table 2 summarizes the genetic findings for our 5 new patients plus 14 prior reported 
patients (19 patients total in 15 families). As noted above, only two patients (Patients 2 
and 10) are compound heterozygous for identical mutations (c.166G>A in cis with 
c.815-27T>C plus c.693+1G>A in trans). 
 Nearly all families (12 of 15) carry the c.815-27T>C branch-site mutation, which 
is not surprising since they are of European descent and this is the highest frequency 
NUBPL variant amongst known pathogenic variants (Table 2), based on the gnomAD 
database (~0.45% in non-Finnish Europeans)[9]. Despite its relatively high frequency in 
the general population, aberrant splicing data, demonstrated in Patient 5[8] and in newly 
reported Patients 1A and 1B and their father (Figure 2), supports its pathogenicity. 
 While the c.815-27T>C branch-site mutation was reported to be hemizygous or 
homozygous in Patient 7[10], parental DNA was unavailable for testing so it is possible 
the patient is heterozygous for c.815-27T>C and has another yet to be characterized 
pathogenic NUBPL variant. We note that the gnomAD database reports ten c.815-27T> 
homozygotes (three non-Finnish European and seven Finnish subjects). It is unlikely 
that subjects with early-onset NUBPL disease would be included in a population 
database. We hypothesize that homozygous subjects have a mild form of NUBPL 
disease (e.g., many may be undiagnosed) or, as Tucker et al.[8] suggested, may be at 
higher risk of developing late-onset neurological disorders such as Parkinson’s disease. 
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 As noted above, we report, for the first time, three patients without the c.166G>A 
[p.G56R] variant in cis with c.815-27T>C. The allele frequency difference between the 
c.166G>A (0.03%) and c.815-27T>C (0.45%) variants infers that they are not always 
found on the same haplotype. Despite in silico prediction that c.166G>A [p.G56R] is 
damaging/deleterious (Table 2), in vitro functional assays do not, thus far, support 
pathogenicity[8]. 
 Besides c.815-27T>C and c.693+1G>A, c.311T>C [p.L104P] (allele frequency 
0.02%) is the only other pathogenic variant found in two or more families (see Families 
1, 3, 13, and 14). As noted above, for patients that share the c.311T>C [p.L104P] 
variant, their clinical symptoms are quite variable depending on which of the three 
pathogenic NUBPL variants (c.815-27T>C, c.287A>T [p.D96V], or c.726C>G [p.F242L]) 
they carry in trans (Tables 1, 2). Finally, we note that 6 of 15 families (5, 8, 11, 12, 13, 
and 15) carry a novel NUBPL variant (i.e., not reported in the gnomAD) in trans with a 




Primary mitochondrial diseases (PMD) are caused by mutations in a large number of 
mitochondrial and nuclear genes, resulting in a broad range of phenotypes that are 
often present in other diseases[22]. As a subclass of PMD, complex I deficiency is one 
of the most common, with 34 nuclear genes now recognized to cause autosomal 
recessive disease[2]. Complex I assembly factor gene NUBPL (MIM 613621), 1 of 12 
assembly factors known to cause disease[2, 5] was first reported to cause complex I 
deficiency (MIM 618242) in 2010[3]. Prior to this report on clinical and genetic findings 
in 5 new patients, only 14 cases were known worldwide[3, 10-15]. 
We have presented evidence that four of our five patients have NUBPL complex I 
deficiency symptoms consistent with other known patients (all patients are summarized 
in Table 1). In addition to cerebellar atrophy (Table 1), brain MRIs (Figure 1B) showed 
progressive global cerebellar hypoplasia  with both vermis and cortex involved, in 
addition to hypoplasia of the medulla and pons. Consistent with cerebellar involvement, 
ataxia, dysarthria, nystagmus, and tremor were usually found, which was also noted in 
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prior patients, along with spasticity. Biochemical findings (e.g., complex I defects and 
high lactate), when available, were not a consistent indicator of mitochondrial 
dysfunction in our patients or prior patients. Patient 4 was suspected of having NUBPL 
disease, but neither his brain MRI (Figure 1B) or yeast model functional experiments for 
his c.545T>C [p.V182A] variant (Figure 4) are supporting evidence. He also has a 
16p12.1 deletion (Figure 1A, Table 1) and this possibly explains his neurological 
symptoms[21]. 
None of the four NUBPL variants found in our five new patients (1A, 1B, 2, and 3) 
with NUBPL disease are novel. Variants c.815-27T>C and c.166G>A [p.G56R], 
reported to be in cis for most patients[3, 10], were found in Patients 2 and 3. However, 
Patients 1A and 1B (and suspected Patient 4) are the first reported patients that do not 
have c.166G>A. This supports the conclusion by Tucker et al.[8] that c.815-27T>C, by 
itself, is a pathogenic variant as their in vitro experiments did not show that p.G56R was 
deleterious. Our Patient 2 is the first reported case with identical mutations (c.815-
27T>C and c.166G>A in cis plus c.693+1G>A in trans) as a prior patient[10]. Variant 
c.311T>C [p.L104P], found in Families 1 and 3 (Figure 1A), was originally reported for 
Patient 1A without a clinical description[16]. Recently it was reported in compound 
heterozygous patients that had either c.287A>T [p.D96V][11] or c.726C>G 
[p.F242L][13], but their phenotypes (see Table 1, Patients 13A, 13B, and 14) were 
distinct from our patients and prior patients that all had in common the c.815-27T>C 
variant. Similarly, Patients 15A and 15B, who also lack c.815-27T>C, have distinctive 
clinical features (e.g., thalamic involvement)[15]. They have the same splicing mutation 
(c.693+1G>A) as Patients 2 and 10 plus a novel mutation (p.M117I). These findings 
underscore that, even for a single gene, phenotypes can vary significantly. 
On a broader level, there are two observations in common between NUBPL and 
three other complex I assembly factors: NDUFAF5, NDUFAF6, and NDUFAF8. First, 
NDUFAF6 has also been linked to dystonia and BSN[23], which are clinical findings in 
NUBPL patients that are compound heterozygous for p.D96V and p.L104P[11]. Second, 
analgous to NUBPL c.815-27T>C, aberrant splicing variants that do not involve a splice 
donor or acceptor have been reported for NDUFAF5 (c.223-907A>C)[24] and NDUFAF8 
(c.195+271C>T)[25]. Such variants may be difficult to uncover in WES bioinformatics 
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pipelines that exclude intronic and/or common variants. This is a particularly important 
issue for c.815-27T>C due to its ~1% frequency in the European ancestry population 
(i.e., we suspect that complex I deficiency patients with this splicing mutation are 
underdiagnosed). 
With such a limited number of NUBPL disease patients, now eighteen total with 
our four new patients, there are several open genotype-phenotype questions. First, with 
additional evidence that c.815-27T>C by itself is pathogenic (Patients 1A and 1B), what 
phenotypes, if any, are found in c.815-27T>C homozygotes (ten are reported in 
gnomAD)? Second, does c.815-27T>C confer an alternate clinical picture compared to 
patients without it? Third, despite lack of evidence thus far from in vitro studies, does 
p.G56R contribute to the complex I deficiency phenotype? Fourth, what genetic 
backgrounds and/or environmental factors contribute to varying degrees of severity in 
patients with the same mutations (either siblings or in unrelated patients like Patients 2 
and 10 in Table 1)? Finally, new treatments are needed, which are currently limited to 
mitochondrial cocktails (e.g., supplements of coenzyme Q10, carnitine, and α-lipoic 
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Figure 1  New patients with NUBPL disease. (A) Pedigree charts for five new patients 
(four families). Circles indicate females and squares males, arrow P = Proband. Family 
4 has a suspected patient (see text). (B) Cross section of brain MRIs in all subjects 
(Patients 1A and 1B show MRIs for two different ages). Cerebellar and pons hypoplasia 
are noted (and cerebellar atrophy) except in Patient 4, who had normal brain anatomy 
except slightly prominent Sylvian fissures/subarchnoid spaces. (C) Cerebellar brain 
biopsy for Patient 1A at age one year with hematoxylin and eosin (H&E) stain (left 
panel) and neurofilament (NF) antibody stain (right panel, same region as left panel). 
The biopsy shows abnormal foliar architecture with large and irregularly distributed 
Purkinje neurons (highlighted with Neurofilament protein 
immunohistochemistry), Bergmann gliosis, and widespread karyorrhexis of the internal 
granular cell layer. 
  
Figure 2  Alternatively spliced transcripts levels are higher in NUBPL c.815-27T>C 
carriers. (A) CloneSeq results for the splice variants observed in Family 1 are displayed 
as Sashimi plots, wherein transcript levels are quantified as Reads Per Kilobase of 
transcript, per Million mapped reads (RPKM). These provide an absolute number of 
aligned reads (numbers are indicated for each family member) that enables comparison 
of exon usage across the carriers (Sister+, Proband+, Father+), non-carriers (Mother-, 
Sister-), and controls (Blood control-, Brain control-). In addition to normal transcript, two 
alternate transcripts were observed: r.815_897del83 (exon 10 skipping) and r.815-
72_815-1ins72 (partial inclusion of intron 9). (B) The relative expression of the two 
alternatively spliced transcripts are displayed as Percent Splicing Index (PSI). Higher 
levels of both alternate transcripts were observed only in c.815-27T>C carriers. 
 
Figure 3  Mitochondrial respiration is impaired in NUBPL patient fibroblasts. (A) Oxygen 
consumption rate (OCR) traces were measured in fibroblast cell lines from NUBPL 
patients 1A, 1B, and 2 and a control cell line using the Seahorse XF Cell Mito Stress 
Test. Three measurements were taken for each stage of the assay: the initial OCR; 
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OCR after injection of oligomycin; OCR after injection of FCCP; and OCR after injection 
of rotenone + antimycin A. The OCR values are normalized by total protein for each 
well. (B) Basal respiration and spare respiratory capacity for NUBPL patient and control 
fibroblast cell lines, calculated using Mito Stress Test report generator software. Basal 
respiration is calculated by subtracting the non-mitochondrial OCR (lowest 
measurement after the injection of rotenone + antimycin A) from the initial OCR (last 
measurement before the injection of oligomycin). Spare respiratory capacity is 
calculated by subtracting the initial OCR from the maximal OCR (maximal measurement 
after injection of FCCP). Error bars are the standard deviation; statistical significance 
was calculated using student’s t-test. The results show that the spare respiratory 
capacity for all three patients was less than control. 
 
Figure 4  p.V182A substitution does not impact function of the NUBPL homolog in a 
yeast model. (A) Alignment of the amino acid sequence surrounding valine 182 (V182) 
in NUBPL from human (NP_079428.2) and the homologous Ind1 protein from Yarrowia 
lipolytica (XP_501064.1). Conserved residues are shaded black. Position V182 is semi-
conserved (shaded grey), with a methionine present at the corresponding position in 
Ind1 (M180). (B) Complex I levels in the Ind1 M180V and M180A variants compared to 
control (ind1 deletion mutant expressing the wild-type IND1 gene from a plasmid and an 
ind1 deletion mutant ind1Δ). Complex I was visualised by NADH/NBT staining of Blue-
Native Poly-Acrylamide Gel Electrophoresis (BN-PAGE) gels. Ind1 and Aco1 protein 
levels were detected by SDS-PAGE and immunoblot analysis. (C) Assembly 
intermediates of complex I containing the NUCM subunit (NDUFS2 in human), 
visualised by BN-PAGE and immunoblotting. (D) Growth of the indicated Yarrowia yeast 
strains at normal and cold temperatures. Images show a serial dilution of cultures that 
were spotted onto agar plates. 
 
